Lifestyle impacts NHL prognosis, say Mayo Clinic Researchers

According to a study carried out by researchers chiefly at the Mayo Clinic, lifestyle risk factors that exist prior to receiving a diagnosis of non-Hodgkin's lymphoma can seriously—and negatively—impact prognosis, specifically overall survival. Notably:

-- NHL patients with a history of smoking for 20 years or more have a 76 percent higher risk of death when compared to NHL patients who never smoked.

-- NHL patients with a history of drinking "more than 43 grams of alcohol per week" have a 55 percent higher risk of death when compared to NHL patients who did not drink.

-- NHL patients who are obese (BMI of 30 or higher) have a 32 percent higher risk of death compared to NHL patients who are not obese.

This is the first US study to look at the effects of these risk factors following diagnosis, and it suggests that altering one's lifestyle following diagnosis could favorably impact one's prognosis, although researchers caution that such a suggestion has not been put to the clinical test.

COHORT

This study used information from 1,286 NHL patients from various US states.

PUBLICATIONS

These results were published online in the journal Cancer.

By Ross Bonander

Source: EurekAlert

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap